Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Get Free Report) insider Neal Flomenberg sold 1,078,600 shares of the company's stock in a transaction on Thursday, October 17th. The stock was sold at an average price of $1.62, for a total value of $1,747,332.00. Following the sale, the insider now directly owns 4,254,302 shares in the company, valued at $6,891,969.24. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Tevogen Bio Stock Performance
TVGN stock opened at $1.80 on Tuesday. The company's 50 day moving average price is $0.58 and its 200 day moving average price is $0.85. Tevogen Bio Holdings Inc. has a fifty-two week low of $0.26 and a fifty-two week high of $21.09.
Wall Street Analysts Forecast Growth
Separately, Fundamental Research set a $4.20 price target on Tevogen Bio and gave the stock a "buy" rating in a report on Friday, June 28th.
Read Our Latest Analysis on TVGN
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Tevogen Bio stock. Portland Global Advisors LLC acquired a new position in shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN - Free Report) in the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 5,782,209 shares of the company's stock, valued at approximately $21,683,000. Tevogen Bio comprises approximately 3.0% of Portland Global Advisors LLC's investment portfolio, making the stock its 9th largest position. Portland Global Advisors LLC owned about 36.55% of Tevogen Bio at the end of the most recent reporting period.
Tevogen Bio Company Profile
(
Get Free Report)
Election warning coming true…
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - watch it before it's too late.
Click here to watch it now.
Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
